Cassava Sciences, Inc.

SAVA
Brazeau v. Cassava Sciences, Inc. et al, (Case No. 1:21cv00751), W.D. Tex.

On August 24, 2021, after market hours, Cassava Sciences stock dropped over 20% in response to a report raising concerns over the quality of the studies into the Company’s experimental Alzheimer’s drug simufilam. A letter posted on a government website urged the U.S. Food and Drug Administration’s (FDA) center for drug evaluation and research to pause simufilam clinical trials.

On this news, Cassava’s stock price plunged over 20%, in after hours trading on August 24, 2021.

Lead Plaintiff deadline
October 26, 2021
class period
September 14, 2020
to
August 27, 2021
Case Documents
No documents available. Contact us if you need a case document.